Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.

Tanuma J, Jiamsakul A, Makane A, Avihingsanon A, Ng OT, Kiertiburanakul S, Chaiwarith R, Kumarasamy N, Nguyen KV, Pham TT, Lee MP, Ditangco R, Merati TP, Choi JY, Wong WW, Kamarulzaman A, Yunihastuti E, Sim BL, Ratanasuwan W, Kantipong P, Zhang F, Mustafa M, Saphonn V, Pujari S, Sohn AH; TREAT Asia HIV Observational Databases (TAHOD).

PLoS One. 2016 Aug 25;11(8):e0161562. doi: 10.1371/journal.pone.0161562. eCollection 2016.

2.

Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.

Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, Gatanaga H, Oka S.

AIDS Patient Care STDS. 2017 Mar;31(3):105-112. doi: 10.1089/apc.2016.0286.

3.

Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?

Marcelin JR, Berg ML, Tan EM, Amer H, Cummins NW, Rizza SA.

PLoS One. 2016 Feb 12;11(2):e0149562. doi: 10.1371/journal.pone.0149562. eCollection 2016.

4.

Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.

Cao Y, Han Y, Xie J, Cui Q, Zhang L, Li Y, Li Y, Song X, Zhu T, Li T.

BMC Infect Dis. 2013 Jul 1;13:301. doi: 10.1186/1471-2334-13-301.

5.

Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.

Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, Wandeler G; IeDEA-Southern Africa.

Clin Infect Dis. 2014 May;58(10):1473-80. doi: 10.1093/cid/ciu117. Epub 2014 Feb 27.

6.

Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.

Chikwapulo B, Ngwira B, Sagno JB, Evans R.

Int J STD AIDS. 2018 Jun;29(7):650-657. doi: 10.1177/0956462417749733. Epub 2018 Jan 16.

PMID:
29334883
7.

Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.

Huang YS, Chan CK, Tsai MS, Lee KY, Lin SW, Chang SY, Hung CC, Chang SC.

J Microbiol Immunol Infect. 2017 Oct;50(5):595-603. doi: 10.1016/j.jmii.2015.08.019. Epub 2015 Sep 9.

8.

Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Quesada PR, Esteban LL, García JR, Sánchez RV, García TM, Alonso-Vega GG, Ferrández JS.

Int J Clin Pharm. 2015 Oct;37(5):865-72. doi: 10.1007/s11096-015-0132-1. Epub 2015 May 26.

PMID:
26008219
9.

Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study.

De Waal R, Cohen K, Fox MP, Stinson K, Maartens G, Boulle A, Igumbor EU, Davies MA.

J Int AIDS Soc. 2017 Apr 10;20(1):21317. doi: 10.7448/IAS.20.01/21317. Erratum in: J Int AIDS Soc. 2017 Jun 2;20(1):22066.

10.

Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.

Jose S, Hamzah L, Campbell LJ, Hill T, Fisher M, Leen C, Gilson R, Walsh J, Nelson M, Hay P, Johnson M, Chadwick D, Nitsch D, Jones R, Sabin CA, Post FA; UK Collaborative HIV Cohort Study Steering Committee.

J Infect Dis. 2014 Aug 1;210(3):363-73. doi: 10.1093/infdis/jiu107. Epub 2014 Feb 28.

11.

The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.

Salome T, Kasamba I, Mayanja BN, Kazooba P, Were J, Kaleebu P, Munderi P; CoLTART study team.

AIDS Res Ther. 2016 Aug 30;13(1):28. doi: 10.1186/s12981-016-0113-z. eCollection 2016.

12.

Renal outcomes after up to 8 years of tenofovir exposure in HIV-HBV-coinfected patients.

Boyd A, Miailhes P, Lascoux-Combe C, Rougier H, Girard PM, Plaisier E, Lacombe K.

Antivir Ther. 2017;22(1):31-42. doi: 10.3851/IMP3076. Epub 2016 Aug 24.

PMID:
27553871
13.

Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir.

Casado JL, Bañón S, Santiuste C, Serna J, Guzman P, Tenorio M, Liaño F, del Rey JM.

AIDS. 2016 Jan;30(2):231-9. doi: 10.1097/QAD.0000000000000901.

PMID:
26684820
14.

Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.

Hamzah L, Jose S, Booth JW, Hegazi A, Rayment M, Bailey A, Williams DI, Hendry BM, Hay P, Jones R, Levy JB, Chadwick DR, Johnson M, Sabin CA, Post FA.

J Infect. 2017 May;74(5):492-500. doi: 10.1016/j.jinf.2017.01.010. Epub 2017 Jan 25.

15.

Changes in Kidney Function and in the Rate of Tubular Dysfunction After Tenofovir Withdrawal or Continuation in HIV-Infected Patients.

Casado JL, Del Rey JM, Bañón S, Santiuste C, Rodriguez M, Moreno A, Perez-Elías MJ, Liaño F, Moreno S.

J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):416-22. doi: 10.1097/QAI.0000000000000986.

PMID:
26962850
16.

Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients.

Gupta SK, Anderson AM, Ebrahimi R, Fralich T, Graham H, Scharen-Guivel V, Flaherty JF, Fortin C, Kalayjian RC, Rachlis A, Wyatt CM.

PLoS One. 2014 Mar 20;9(3):e92717. doi: 10.1371/journal.pone.0092717. eCollection 2014.

17.
18.

Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.

Lee KH, Lee JU, Ku NS, Jeong SJ, Han SH, Choi JY, Song YG, Kim JM.

Yonsei Med J. 2017 Jul;58(4):770-777. doi: 10.3349/ymj.2017.58.4.770.

19.

Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou HK, Baldassari S, Palma P, Bernardi S.

BMC Infect Dis. 2012 Jan 23;12:18. doi: 10.1186/1471-2334-12-18.

20.

Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.

Mugwanya KK, Wyatt C, Celum C, Donnell D, Kiarie J, Ronald A, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):374-80. doi: 10.1097/QAI.0000000000000868.

Supplemental Content

Support Center